BioMedNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) to Postpone February Virtual Road Show

Trxade Group (NASDAQ: MEDS), an integrated drug-procurement, delivery and healthcare platform, has announced that it will postpone its upcoming virtual road show. Trxade had previously announced that the road show event would be held Wednesday, Feb. 3, 2021, at 11 a.m. ET. The company, which operates across the United States in all 50 states, will reschedule the event and announce the new date and time. Trxade Group is committed to its mission of making healthcare services affordable and accessible. “The virtual roadshow will be postponed to a later date, which will be announced via press release accompanied by a webcast link and dial-in numbers once finalized,” said Trxade Group CEO Suren Ajjarapu in the press release. “I would like to thank our shareholders for their patience as we continue to execute upon our near-term business objectives. I look forward to presenting an overview of the business model, short-term growth initiatives and a corporate update to both new and prospective investors.”

To view the full press release, visit https://ibn.fm/VuUVC

About Trxade Group Inc.

Headquartered in Tampa, Florida, Trxade Group is an integrated drug procurement, delivery and healthcare platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making healthcare services affordable and accessible. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; (1) the Trxade B2B trading platform with around 11,800 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; and (3) the Bonum Health platform offering affordable telehealth services. For more information about the company, please visit www.Trxade.com and www.BonumHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces First Patient Dosed in Phase 1b Trial of Sapu003

Oncotelic Therapeutics (OTCQB: OTLC), alongside Sapu Nano, announced that the first patient has been dosed in the Phase 1b clinical trial…

18 hours ago

BioMedNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid…

20 hours ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Next-Generation CNS Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC) was featured in BioMedWire editorial coverage examining the growing urgency around…

21 hours ago

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Spotlighted in BioMedWire Editorial on AI-Driven Impairment Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio…

21 hours ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Enters $4.4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced a definitive agreement for…

21 hours ago

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation 

This article has been disseminated on behalf of SureNano Science Ltd.  and may include paid advertising.  SureNano Science (CSE: SURE) (OTCQB:…

2 days ago